154 related articles for article (PubMed ID: 18678789)
1. Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease.
White WB; Salzman P; Schwid SR;
Hypertension; 2008 Sep; 52(3):587-93. PubMed ID: 18678789
[TBL] [Abstract][Full Text] [Related]
2. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.
deMarcaida JA; Schwid SR; White WB; Blindauer K; Fahn S; Kieburtz K; Stern M; Shoulson I; ;
Mov Disord; 2006 Oct; 21(10):1716-21. PubMed ID: 16856145
[TBL] [Abstract][Full Text] [Related]
3. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
Parkinson Study Group
Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
[TBL] [Abstract][Full Text] [Related]
4. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E;
Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996
[TBL] [Abstract][Full Text] [Related]
5. The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?
Chen JJ; Wilkinson JR
J Clin Pharmacol; 2012 May; 52(5):620-8. PubMed ID: 21628600
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline.
Goren T; Adar L; Sasson N; Weiss YM
J Clin Pharmacol; 2010 Dec; 50(12):1420-8. PubMed ID: 20445015
[TBL] [Abstract][Full Text] [Related]
8. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Guay DR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
[TBL] [Abstract][Full Text] [Related]
9. Rasagiline adjunct therapy in patients with Parkinson's disease: post hoc analyses of the PRESTO and LARGO trials.
Elmer LW
Parkinsonism Relat Disord; 2013 Nov; 19(11):930-6. PubMed ID: 23849501
[TBL] [Abstract][Full Text] [Related]
10. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.
Parkinson Study Group
Arch Neurol; 2004 Apr; 61(4):561-6. PubMed ID: 15096406
[TBL] [Abstract][Full Text] [Related]
11. Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease.
Stocchi F; Rabey JM
Eur J Neurol; 2011 Dec; 18(12):1373-8. PubMed ID: 21895884
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of adjunctive rasagiline in Japanese Parkinson's disease patients with wearing-off phenomena: A phase 2/3, randomized, double-blind, placebo-controlled, multicenter study.
Hattori N; Takeda A; Takeda S; Nishimura A; Kato M; Mochizuki H; Nagai M; Takahashi R
Parkinsonism Relat Disord; 2018 Aug; 53():21-27. PubMed ID: 29748109
[TBL] [Abstract][Full Text] [Related]
13. Rasagiline for motor complications in Parkinson's disease.
Clarke CE
Lancet; 2005 Mar 12-18; 365(9463):914-6. PubMed ID: 15766976
[No Abstract] [Full Text] [Related]
14. Determination of Monoamine Oxidase A and B Activity in Long-Term Treated Patients With Parkinson Disease.
Müller T; Riederer P; Grünblatt E
Clin Neuropharmacol; 2017; 40(5):208-211. PubMed ID: 28682929
[TBL] [Abstract][Full Text] [Related]
15. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa.
Rabey JM; Sagi I; Huberman M; Melamed E; Korczyn A; Giladi N; Inzelberg R; Djaldetti R; Klein C; Berecz G;
Clin Neuropharmacol; 2000; 23(6):324-30. PubMed ID: 11575866
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson's disease.
Viallet F; Pitel S; Lancrenon S; Blin O
Curr Med Res Opin; 2013 Jan; 29(1):23-31. PubMed ID: 23176073
[TBL] [Abstract][Full Text] [Related]
17. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients.
Stern MB; Marek KL; Friedman J; Hauser RA; LeWitt PA; Tarsy D; Olanow CW
Mov Disord; 2004 Aug; 19(8):916-23. PubMed ID: 15300656
[TBL] [Abstract][Full Text] [Related]
18. Rasagiline: time to onset of antiparkinson effect is similar when used as a monotherapy or adjunct treatment.
Wilson RE; Seeberger LC; Silver D; Griffith A; Conner JB; Salzman PM;
Neurologist; 2011 Nov; 17(6):318-24. PubMed ID: 22045282
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease.
Tolosa E; Stern MB
Eur J Neurol; 2012 Feb; 19(2):258-64. PubMed ID: 21819487
[TBL] [Abstract][Full Text] [Related]
20. Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial.
Weintraub D; Hauser RA; Elm JJ; Pagan F; Davis MD; Choudhry A;
Mov Disord; 2016 May; 31(5):709-14. PubMed ID: 27030249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]